Portfolio category: All
Trauma-INTACT
Trauma-INTACT is a prospective, open-label, multicentre, pharmacokinetic study. Objective: To assess the population pharmacokinetics of intramuscular TXA in trauma patients. Background: The anti-fibrinolytic TXA has been licensed for over 30 years for use in the prevention and treatment of haemorrhage. More recently, large clinical trials have shown that TXA reduces death from bleeding after trauma and post-partum haemorrhage
Details